OR WAIT 15 SECS
January 21, 2016.
The small cell lung cancer (SCLC) treatment market will rise from $198 million in 2014 to $2.29 billion by 2024, according to research and consulting firm GlobalData.
The company’s latest report states that the growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents.
GlobalData analyst Volkan Gunduz, Ph.D., says novel SCLC therapies will experience strong and rapid adoption during the forecast period in combination with generic, chemotherapy-only regimens in the early lines of therapy, and extend the number of lines of treatment available for patients. It is reported that SCLC treatment sales will also be bolstered by an increase in rates of the disease across the five European markets (5EU) and Japan, at a CAGR of 1.49% over the forecast period.